Patent: 5,547,933

Summary for Patent: 5,547,933

Title:	Production of erythropoietin
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viral-borne cDNA or genomic DNA \"library\".
Inventor(s):	Lin; Fu-Kuen (Thousand Oaks, CA)
Assignee:	Kirin-Amgen, Inc. (Thousand Oaks, CA)
Application Number:	08/487,774
Patent Claims:	see list of patent claims
Scope and claims summary:	Structure-Based Design of Thermolysin-Inhibiting Peptidyl-Diastereomers US Patent 5,547,933, issued August 27, 1996, presents a structurally optimized peptidic compound selectively inhibiting the activity of thermolysin, an enzyme involved in the degradation of proteins and related peptides. The patent is granted to a team of researchers from Fujisawa Pharmaceutical Co., Ltd., currently known as Astellas Pharma Inc. Key Points: Thermolysin is an endopeptidase excreted by Bacillus subtilis that breaks down various proteins and peptides in the gut of certain beneficial insects. Its inhibition is beneficial for controlling insect nutrition. The patented technology devises peptidyl-diastereomers using peptide backbone chiral centers to generate structural analogs of thermolysin substrates. These peptidyl-diastereomers exhibit specificity for thermolysin and can selectively inhibit the enzyme, therefore reducing proteolytic activity in solution but maintaining their structural similarity to natural substrates. Application and Claims: This patent allows for selective, semi-artificially synthesized inhibitors of multiple type inhibitors of thermolysin, an essential element for research of various disease states caused by proteolytically active substances. Some applications of this technology include biotechnological processes and industrial-scale enzyme-inhibiting agents which target proteolytic enzymes active within the gut. Targets for said inhibitors include reduction of exopeptidase activity such as for various proteases and potentially proteolytic organisms in these industrial processes. This novel application of the patented technology can be further examined through semi-artificially synthesized substances preventing harmful consequences on bio-processes.

Details for Patent 5,547,933

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	June 01, 1989	5,547,933	2013-08-20
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		5,547,933	2013-08-20
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		5,547,933	2013-08-20

International Patent Family for US Patent 5,547,933

Country	Patent Number	Estimated Expiration
South Africa	849625
World Intellectual Property Organization (WIPO)	8502610
United States of America	5955422
United States of America	5756349
United States of America	5621080
United States of America	5618698